NeoCore Technology Co

NeoCore Technology Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of NeoCore Technology Co (4131.TWO) as of Nov 11, 2026 is 144.71 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 116.66 % — a change of 24.04% (higher).

FCF Conversion

144.71 %

YoY

24.04%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of NeoCore Technology Co is 2024 144.71 % . FCF Conversion Rate (FCF/EBITDA) of NeoCore Technology Co was 2023 116.66 % . It decreases by 24.04% higher compared to the previous year.

The NeoCore Technology Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
-174.29 TWD
Jan 1, 2018
111.32 TWD
Jan 1, 2019
39.90 TWD
Jan 1, 2020
103.34 TWD
Jan 1, 2021
99.75 TWD
Jan 1, 2022
12.14 TWD
Jan 1, 2023
116.66 TWD
Jan 1, 2024
144.71 TWD
The NeoCore Technology Co FCF Conversion history
YEARFCF ConversionYoY
144.71 %+24.04%
116.66 %+860.77%
12.14 %-87.83%
99.75 %-3.48%
103.34 %+159.01%
39.90 %-64.16%
111.32 %-163.87%
-174.29 %-304.61%
85.18 %-127.96%
-304.63 %-153.89%
565.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NeoCore Technology Co Stock analysis

What does NeoCore Technology Co do? NeoCore Technology Co Ltd generates revenue through the sale of biochips and related biotechnology products. The company develops and manufactures DNA/RNA sample preparation kits, polymerase chain reaction kits, rapid hybridization equipment, biochips, testing reagents, biological preparations, nucleic acid sequencing detection systems, biotechnology control hardware and software, and biomedical materials. These products are primarily sold within Taiwan and exported to Asian and European markets. The company's domestic sales focus on the Taiwanese market while international exports target Asian and European customers. DR. Chip Biotechnology, Inc. operates as the parent company for NeoCore Technology Co Ltd, managing the research, development, manufacturing, and sales of biochips. The business model relies on direct sales of its comprehensive product portfolio to domestic and international clients in the biotechnology sector. The company's product range serves both laboratory and commercial applications within the biotechnology industry. NeoCore Technology Co Ltd's revenue streams include the sale of biochips, DNA/RNA sample preparation kits, polymerase chain reaction kits, and related components. The company's export focus on Asia and Europe drives international sales, while domestic sales in Taiwan form a significant portion of its business. The company's product offerings cater to the needs of biotechnology laboratories and commercial entities requiring advanced biotech solutions. NeoCore Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NeoCore Technology Co stock

FCF Conversion Rate (FCF/EBITDA) of NeoCore Technology Co is 144.71 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of NeoCore Technology Co changed from 116.66 % to 144.71 %, representing a 24.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) NeoCore Technology Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s NeoCore Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NeoCore Technology Co

All Key Metrics — NeoCore Technology Co